Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharma, Eli Lilly accelerate antibody therapies in Greater China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Mabylon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research and Option Agreement in the Field of CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciNeuro Completes Dosing in its Phase 1 Clinical Trial of SNP318, an Oral Therapeutic for Alzheimer's Disease and Other Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by SciNeuro Pharmaceuticals

    Menu

    SciNeuro Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              SciNeuro Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SciNeuro Completes Dosing in its Phase 1 Clinical Trial of SNP318, an Oral Therapeutic for Alzheimer's Disease and Other Neurodegenerative Diseases

              Details:

              SNP318 is a small molecule oral inhibitor which works by targeting Lp-PLA2, it is currently being investigated for the treatment of Alzheimer Disease.

              Lead Product(s): SNP318

              Therapeutic Area: Neurology Product Name: SNP318

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SciNeuro Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases

              Details:

              SNP318 is a small molecule, optimized for CNS penetrance, to induce broader anti-inflammatory benefits. It is being investigated as a novel Lp-PLA2 inhibitor targeting neurodegenerative and inflammatory diseases.

              Lead Product(s): SNP318

              Therapeutic Area: Ophthalmology Product Name: SNP318

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SciNeuro Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research and Option Agreement in the Field of CNS Diseases

              Details:

              Under the collaboration, the companies will work together to generate novel Antisense Oligonucleotide therapies directed at targets that play a critical role in diseases of the Central Nervous System.

              Lead Product(s): Antisense Oligonucleotide

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Recipient: Secarna Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SciNeuro Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases

              Details:

              Under the agreement, SciNeuro will receive a worldwide license to intellectual property covering certain GSK Lp-PLA2 inhibitors including SNP318 and will be responsible for their further development through clinical proof-of-concept (PoC).

              Lead Product(s): SNP318

              Therapeutic Area: Neurology Product Name: SNP318

              Highest Development Status: IND Enabling Product Type: Undisclosed

              Recipient: GSK

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SciNeuro Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases

              Details:

              SciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA binding protein-43 (TDP-43) and Apolipoprotein E (APOE) for neurodegenerative diseases for which there are currently no effective treatments.

              Lead Product(s): Human Auto-antibodies

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mabylon

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SciNeuro Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SciNeuro Pharma, Eli Lilly accelerate antibody therapies in Greater China

              Details:

              Under the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.

              Lead Product(s): Antibody therapies

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Eli Lilly

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY